Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter J Goebell

Showing results (1-10 of 107) with videos related to

Pageof 11
Sort By:
Urologie (Heidelberg, Germany)|July 24, 2023
[Another encroachment on our liberal profession-The German Federal Ministry of Health continues to stubbornly ignore the self-government]Peter J Goebell
Nature Reviews. Urology|February 15, 2012
Bladder cancer: validity of the 2004 system for grading Ta bladder cancerMaximilian Burger, Peter J Goebell
Urologic Oncology|July 9, 2010
Bladder cancer or bladder cancers? Genetically distinct malignant conditions of the urotheliumPeter J Goebell, Margaret A Knowles
Urologic Oncology|July 9, 2010
New concepts of biobanks--strategic chance for uro-oncologyPeter J Goebell, Manuel M Morente
Urologie (Heidelberg, Germany)|April 29, 2026
Angelika Borkowetz, Peter J Goebell, G Niegisch
Future Oncology (London, England)|March 26, 2025
Contemporary real-world treatment in metastatic hormone-sensitive prostate cancer: US, four European countries, and UKPeter J Goebell, Stephanie Chen, Jay Jhaveri
Aktuelle Urologie|February 5, 2026
[Drug-Drug Interactions as a Challenge in the Monotherapy of Advanced or Metastatic Clear-Cell Renal Cell Carcinoma with VEGFR-Associated Tyrosine Kinase Inhibitors]Hartmut Reinbold, Peter J Goebell, Axel S Merseburger
The Journal of Urology|June 7, 2002
Evaluation of an unconventional treatment modality with mistletoe lectin to prevent recurrence of superficial bladder cancer: a randomized phase II trialPeter J Goebell, Thomas Otto, Julia Suhr, et al.
World Journal of Urology|February 7, 2008
Guidelines for development of diagnostic markers in bladder cancerPeter J Goebell, Susan L Groshen, Bernd J Schmitz-Dräger
Urologic Oncology|July 9, 2010
p53 immunohistochemistry in bladder cancer--a new approach to an old questionPeter J Goebell, Susan G Groshen, Bernd J Schmitz-Dräger, et al.
Pageof 11

Showing results (1-10 of 107) with videos related to

Sort By:
Pageof 11
Urologie (Heidelberg, Germany)|July 24, 2023
[Another encroachment on our liberal profession-The German Federal Ministry of Health continues to stubbornly ignore the self-government]Peter J Goebell
Nature Reviews. Urology|February 15, 2012
Bladder cancer: validity of the 2004 system for grading Ta bladder cancerMaximilian Burger, Peter J Goebell
Urologic Oncology|July 9, 2010
Bladder cancer or bladder cancers? Genetically distinct malignant conditions of the urotheliumPeter J Goebell, Margaret A Knowles
Urologic Oncology|July 9, 2010
New concepts of biobanks--strategic chance for uro-oncologyPeter J Goebell, Manuel M Morente
Urologie (Heidelberg, Germany)|April 29, 2026
Angelika Borkowetz, Peter J Goebell, G Niegisch
Future Oncology (London, England)|March 26, 2025
Contemporary real-world treatment in metastatic hormone-sensitive prostate cancer: US, four European countries, and UKPeter J Goebell, Stephanie Chen, Jay Jhaveri
Aktuelle Urologie|February 5, 2026
[Drug-Drug Interactions as a Challenge in the Monotherapy of Advanced or Metastatic Clear-Cell Renal Cell Carcinoma with VEGFR-Associated Tyrosine Kinase Inhibitors]Hartmut Reinbold, Peter J Goebell, Axel S Merseburger
The Journal of Urology|June 7, 2002
Evaluation of an unconventional treatment modality with mistletoe lectin to prevent recurrence of superficial bladder cancer: a randomized phase II trialPeter J Goebell, Thomas Otto, Julia Suhr, et al.
World Journal of Urology|February 7, 2008
Guidelines for development of diagnostic markers in bladder cancerPeter J Goebell, Susan L Groshen, Bernd J Schmitz-Dräger
Urologic Oncology|July 9, 2010
p53 immunohistochemistry in bladder cancer--a new approach to an old questionPeter J Goebell, Susan G Groshen, Bernd J Schmitz-Dräger, et al.
Pageof 11